Nader Aboul-Fettouh, MD

Monitoring Response and Setting Expectations: A Long-Term Partnership With Patients

Managing patient expectations on JAK-inhibitor therapy for alopecia areata requires clinicians to establish a long-term frame from the very first prescription conversation.

Even when a JAK inhibitor successfully halts immune-mediated follicular destruction— which it may do relatively early in the treatment course-the biological process of visible hair regrowth lags significantly behind disease suppression. Hair cycling and regeneration from a follicle that has been dormant for months or years takes time that cannot be accelerated pharmacologically, and patients who do not understand this distinction are at risk of concluding, prematurely and incorrectly, that their medication is not working. Discussing this timeline clearly and proactively-framing it as established biology rather than clinical uncertainty-allows patients to remain committed to therapy through the months before visible results emerge. The clinical mantra of "underpromise, overdeliver" is particularly well suited to AA management, where patients who are warned that regrowth will take time are often pleasantly surprised by how much they ultimately recover.

In practice, this means dermatologists should explicitly defer any outcome-oriented assessment of hair regrowth for at least 6 months from the start of therapy, with many practitioners extending that window to 9 or even 12 months for patients who want to give the medication a full opportunity to demonstrate its effect. The follow-up schedule reflects this long arc: an initial visit around the 1-month mark to review laboratory results required for JAK-inhibitor safety monitoring, a follow-up at approximately 3 to 4 months, and then visits every 3 to 6 months depending on stability and response. Patients who are pending prior authorization or appeal can often be bridged with samples to prevent a gap in care. Clinical trial data substantiate the value of patience: SALT scores in pivotal AA trials continued to decrease meaning hair coverage continued to improve through 18 to 24 months of treatment, well beyond the timepoint at which many patients might otherwise have abandoned therapy out of discouragement.

In this closing segment, Nader Aboul-Fettouh, MD, double board-certified dermatologist and fellowship-trained Mohs Micrographic Surgeon and founder and managing director of Blue Ribbon Dermatology in the Dallas area, describes his follow-up protocol for patients on JAK inhibitors and explains the biology behind the extended therapeutic timeline in terms he uses with his own patients. Aboul-Fettouh also reflects on the broader significance of having disease-modifying options available for AA patients who, just a few years ago, had none-

-and closes with direct encouragement for community

dermatologists preparing to write their first JAK-inhibitor prescription for this indication, emphasizing that the resources, manufacturer support, and clinical rewards are all in place to make that first prescription worth writing.

Videos

Aboul-Fettouh outlines his follow-up schedule for patients on JAK inhibitors, explains why he defers any meaningful hair-regrowth conversation until at least 6 months into therapy, and reflects on the reward of guiding patients through a treatment journey that was unavailable to them just a few years ago.

Navigating Insurance Barriers: Prior Authorizations, Appeals, and Manufacturer Support

The availability of effective JAK inhibitors for alopecia areata has not automatically translated into patient access, and for many practices the gap between prescribing and actually getting a patient on therapy represents one of the most operationally demanding aspects of managing this disease. Payers frequently continue to classify AA as a cosmetic condition rather than a medical one position increasingly at odds with the clinical literature documenting its association with anxiety, depression, and significantly reduced scores on standardized quality-of-life instruments such as the DLQI. Prior-authorization requirements, step-therapy mandates, and outright denials are common, and practices that are not prepared to engage systematically with the appeals process risk losing patients to frustration and abandonment of treatment before it ever begins. Proactive documentation, starting at the first visit, is the single most important operational step a practice can take to reduce the frequency of denials and improve the success rate of appeals.

Effective documentation for prior-authorization purposes goes beyond listing the diagnosis and the proposed drug. Serial photographs taken across multiple visits— ideally over 2 or more months-

-that demonstrate disease progression or lack of

response to prior therapies are among the most compelling elements of an authorization package. Quantitative SALT scoring at each visit creates an objective, reproducible record of disease burden. Narrative documentation of the patient's daily functional impact-how often they think about their hair loss, which activities they are avoiding, whether they rely on a hairpiece to leave the house-translates psychosocial impairment into clinical language that payers can evaluate. When an initial authorization is denied, a letter of medical necessity that incorporates consensus statements from the American Academy of Dermatology (AAD) and other professional organizations directly challenges the cosmetic classification and provides the peer-to-peer reviewer with a framework for reconsidering the denial. If that appeal is also unsuccessful, requesting a peer-to-peer call with the payer's medical director creates a final opportunity to advocate directly for the patient's access to care.

In this segment, Nader Aboul-Fettouh, MD, double board-certified dermatologist and fellowship-trained Mohs Micrographic Surgeon and founder and managing director of Blue Ribbon Dermatology in the Dallas area, details the full access landscape for AA systemic therapy-from the initial prior-authorization submission through the appeal and peer-to-peer review process. He also highlights the manufacturer support infrastructure, including bridge programs, copay assistance, and field reimbursement specialists, that has become an indispensable resource for practices managing the administrative burden of getting patients onto approved JAK-inhibitor therapy.

Aboul-Fettouh outlines the documentation strategies, appeal pathways, and manufacturer resources that dermatology practices can leverage to overcome payer barriers and get patients with alopecia areata onto the systemic therapies they need.

A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease

Patients with longstanding alopecia areata who have cycled through prior clinical encounters and been told that no meaningful treatment options exist represent a distinct and emotionally complex patient population. By the time such individuals present to a dermatologist, they have often developed an adaptive relationship with their hair loss: wearing hairpieces or scalp coverings as part of a daily routine, avoiding settings in which their alopecia might be visible, and-critically-having long since stopped expecting medicine to offer anything new. The psychological armor these patients have constructed is understandable and appropriate given the advice they received, but it also means that re-engaging them in treatment planning requires care and credibility.

The clinician must not only introduce the existence of effective new therapies but must also counteract years of accumulated hopelessness in a way that feels grounded rather than oversold.

When a patient in this category is identified-whether through a scheduled consultation or, as sometimes happens, incidentally during a skin exam performed for a separate indication-treatment selection is guided by the same shared decision-making framework applied to any new systemic therapy candidate, with particular attention to the patient's comorbidities, existing medication burden, and personal preferences around dosing. Ritlecitinib, with its straightforward once-daily oral administration and well-characterized safety profile in both adult and adolescent populations, has emerged as a natural fit for patients who want to integrate a new medication as seamlessly as possible into an existing routine. Comorbidities that limit eligibility for other agents may further narrow the decision, and the prescribing dermatologist must review each option carefully before making a recommendation. For patients who have waited years for a solution, setting realistic expectations about the 6- to 12-month timeline to visible regrowth is essential-hope grounded in honesty is more durable than hope built on overpromising.

In this segment, Nader Aboul-Fettouh, MD, double board-certified dermatologist and fellowship-trained Mohs Micrographic Surgeon and founder and managing director of Blue Ribbon Dermatology in the Dallas area, describes a patient he identified during a routine skin examination who had been wearing a hairpiece for many years after being told there was nothing medicine could do for her AA. Aboul-Fettouh walks through the clinical and practical factors that guided the decision to initiate ritlecitinib-including comorbidities that precluded other agents, her strong preference for once-daily dosing. and the particular emotional significance of reintroducing genuine therapeutic hope into a case that had previously been framed, incorrectly, as untreatable.

Aboul-Fettouh recounts a case in which an incidental skin examination revealed longstanding, undertreated AA in a patient who had been told no effective therapy existed, illustrating how the new generation of JAK inhibitors can restore both hair and hope.

Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib

The approval of 3 JAK inhibitors for alopecia areata-baricitinib, ritlecitinib, and deuruxolitinib--represents a transformational moment in a field that, until very recently, had no reliable disease-modifying systemic options. For dermatologists who trained and practiced during the decades when patients with severe or progressive AA had little to offer beyond intralesional injections, topical agents, and off-label immunosuppressants with modest and unpredictable efficacy, the arrival of 3 FDA-approved oral agents is genuinely historic. Patients who 20 to 30 years ago could travel internationally seeking any treatment that reliably restored hair can now access effective therapy through a standard office visit and a prescription. Framing the current moment in those terms-as the beginning of a new treatment era rather than a routine expansion of the formulary— helps both clinicians and patients appreciate what is now possible.

Practical differentiation among the 3 agents is achievable even in the absence of head-to-head comparative trials. Ritlecitinib is approved for adolescents aged 12 and older, making it the appropriate first consideration when earlier intervention in younger patients is the clinical priority. Once-daily oral dosing, available with certain agents, may meaningfully improve adherence in patients managing complex polypharmacy regimens or those who express a strong preference for simplicity. Renal and hepatic dosing adjustments vary across the 3 drugs and must be evaluated in the context of each patient's comorbidity profile before a prescription is written. When an initial agent does not produce adequate hair regrowth after a sufficient trial period, switching to a different JAK inhibitor targeting a distinct molecular mechanism remains a reasonable and clinically supported strategy. The absence of head-to-head data does not mean the drugs are interchangeable-it means that individual patient response must guide sequencing decisions.

In this segment, Nader Aboul-Fettouh, MD, double board-certified dermatologist and fellowship-trained Mohs Micrographic Surgeon and founder and managing director of Blue Ribbon Dermatology in the Dallas area, shares how he navigates the agent-selection conversation with patients newly eligible for systemic therapy. He explains how he weighs age, comorbidities, dosing preferences, and compliance considerations in making an initial recommendation, while conveying to patients that treatment for AA is an iterative process—with multiple viable, FDA-approved options-rather than a single high-stakes decision.

Aboul-Fettouh reviews the 3 FDA-approved JAK inhibitors for alopecia areata, highlighting key differentiators-age indication, dosing convenience, renal and hepatic adjustment requirements, and the potential to switch agents when initial therapy fails to achieve adequate regrowth.

Nader Aboul-Fettouh, MD

Articles